StockFin.ai Try Free →

Torrent Pharmaceuticals Limited (TORNTPHARM)

Healthcare · Pharmaceuticals & Biotechnology · NSE · Updated 16 June 2026

₹4,504 ↑ 37.49% (1Y)

🎯 Key Takeaways

Torrent Pharmaceuticals is in a high-growth phase driven by strategic acquisitions and expanding global market penetration, particularly in the US, Germany, and Brazil. The company has transitioned from steady growth to accelerated expansion following the acquisition of JB Pharma, which contributed to a 21% YoY revenue increase in FY26.
Revenue declined 2.8% QoQ to ₹2,809 in Q3FY25.
⚠️ Integration risk from the JB Pharma acquisition — while contributing to growth, cultural and operational synergies may take time to materialize.

Market Cap

₹1.49 L Cr

P/E Ratio

80.1

Div Yield

0.00%

Promoter

0.0%

✨ Ask AI About TORNTPHARM 📊 Interactive Charts

📖 The Story

Torrent Pharmaceuticals is in a high-growth phase driven by strategic acquisitions and expanding global market penetration, particularly in the US, Germany, and Brazil. The company has transitioned from steady growth to accelerated expansion following the acquisition of JB Pharma, which contributed to a 21% YoY revenue increase in FY26. Management is focused on scaling international operations and integrating new assets while maintaining strong profitability metrics.

📰 What's Happening

In Q4 FY25-26, revenue surged 43% YoY to ₹2,215 crores, with international markets showing robust growth — Brazil up 68%, Germany 30%, the US 16%, and India 31%. The company presented audited results for FY26, reporting consolidated revenue of ₹13,980 crores and net profit of ₹2,138 crores, driven significantly by the JB Pharma acquisition effective January 21, 2026. Management highlighted strong performance across key geographies and shared preliminary results with analysts ahead of formal filings. A rescheduled investor call on May 22, 2026, provided a platform to discuss these results in detail. Additionally, the company proposed a final dividend of ₹9 per share (180% payout) and announced a ₹5,000 crore QIP, both contingent on shareholder approval at the upcoming AGM.

Source: Stock Announcements

📊 Quarterly Results (₹ Cr)

Metric	Q4FY23	Q1FY24	Q2FY24	Q3FY24	Q4FY24	Q1FY25	Q2FY25	Q3FY25
Revenue	2,491	2,591	2,660	2,732	2,745	2,859	2,889	2,809
Operating Profit	736	825	851	924	914	928	923	947
OPM %	29.2%	30.5%	31.0%	31.8%	32.2%	31.6%	32.5%	32.5%
Net Profit	287	378	386	443	449	457	453	503
EPS	₹8.48	₹11.18	₹11.39	₹13.10	₹13.27	₹13.51	₹13.37	₹14.88

Revenue has shown consistent growth over the past eight quarters, with a notable acceleration in recent periods — Q4 FY24 to Q4 FY25-26 saw revenue rise from ₹2,491 crores to ₹4,197 crores (up 68% YoY), reflecting both organic expansion and acquisition impact. Operating margins remain stable around 32%, indicating disciplined cost management despite scale. Net profit and EPS have grown steadily, supporting the positive earnings trajectory. This growth is not purely organic; the JB Pharma acquisition played a pivotal role in elevating full-year revenue and profit levels, as confirmed in the FY26 consolidated results.

🔮 Management Outlook & What's Next

Management expressed confidence in sustained growth momentum, citing strong order books and expanding international footprint. In the FY26 results presentation, they emphasized continued investment in high-margin segments and geographic diversification. While no formal long-term guidance was provided, management indicated expectations of continued double-digit revenue growth in the medium term, underpinned by successful integration of JB Pharma and increasing market share in regulated geographies. The tone was optimistic but grounded in execution risks associated with integration and capital deployment.

Extracted from official company announcements. Not StockFin.ai's opinion.

⚖️ Peer Comparison — Pharmaceuticals & Biotechnology

Company	MCap (₹ Cr)	P/E	ROCE	ROE	D/E
Sun Pharmaceutical Industries Limited	4.51 L Cr	41.3	20.3%	15.1%	0.03
Divi's Laboratories Limited	1.79 L Cr	72.4	22.1%	16.6%	0.00
Torrent Pharmaceuticals Limited	1.49 L Cr	80.1	—	—	—
Cipla Limited	1.16 L Cr	25.4	19.4%	14.6%	0.00
Dr. Reddy's Laboratories Limited	1.12 L Cr	20.0	19.7%	16.6%	0.12
Lupin Limited	1.04 L Cr	36.2	—	—	—
Mankind Pharma Limited	1.03 L Cr	49.2	—	—	—
Zydus Lifesciences Limited	1.02 L Cr	22.5	—	—	—
Aurobindo Pharma Limited	87,806	25.3	—	—	—
Laurus Labs Limited	71,455	356.8	—	—	—

🔗 Peer Stock Analyses

SUNPHARMA DIVISLAB CIPLA DRREDDY LUPIN

⚠️ Risk Factors

1. Integration risk from the JB Pharma acquisition — while contributing to growth, cultural and operational synergies may take time to materialize. 2. Capital dilution risk — the ₹5,000 crore QIP could dilute existing shareholders if market conditions are unfavorable. 3. Currency volatility — significant exposure to international markets (notably Brazil and the US) introduces forex-related earnings volatility. 4. Regulatory and pricing pressure — operating in highly competitive regulated markets like the US and Europe poses margin risks due to pricing erosion and compliance costs.

📋 Recent Filings

🧠 Analyst's Read

Torrent Pharmaceuticals is executing a clear growth strategy through acquisitions and international expansion, supported by strong financial performance and profitability. Investors should monitor the pace of integration of JB Pharma, the utilization of capital from the QIP, and quarterly margin trends in key markets. The company's ability to sustain growth without margin erosion or excessive leverage will be critical to maintaining its premium valuation.

Based on filing content and financial data. Not a recommendation.

✨ Deep Dive with AI on TORNTPHARM

Data sourced from stock announcements. Analysis generated by StockFin.ai.
For informational purposes only — not investment advice. Updated 2026-06-16.